Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06192888 | A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06223516 | Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 1 | 60 | AbbVieINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT00819546 | RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS | active not recruiting | Phase 1 | 29 | Richard Stone, MDOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT02717611 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | active not recruiting | Phase 2 | 60 | Acerta Pharma BVINDUSTRY | 6 | Mar 25, 2026 | clinicaltrials |
| NCT03361852 | Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma | active not recruiting | Phase 1 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04756726 | Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma | active not recruiting | Phase 1 | 224 | C4 Therapeutics, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06645886 | A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 13 | Kumquat Biosciences Inc.INDUSTRY | 8 | Mar 25, 2026 | clinicaltrials |
| NCT04268498 | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma(ADVANCE) | active not recruiting | Phase 2 | 310 | University of MiamiOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT02287311 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)(MABEL) | active not recruiting | Phase 1 | 38 | Baylor College of MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03534323 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | active not recruiting | Phase 1 / Phase 2 | 55 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02503423 | Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | active not recruiting | Phase 1 / Phase 2 | 253 | Taiho Oncology, Inc.INDUSTRY | 8 | Mar 20, 2026 | clinicaltrials |
| NCT02773030 | A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma | active not recruiting | Phase 1 / Phase 2 | 466 | CelgeneINDUSTRY | 11 | Mar 20, 2026 | clinicaltrials |
| NCT02405676 | BNHL-2015 for Children or Adolescents in China(BNHL-2015) | active not recruiting | Phase 2 / Phase 3 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04629729 | FT819 in Subjects With B-cell Malignancies | active not recruiting | Phase 1 | 54 | Fate TherapeuticsINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04726501 | CCCG-HD-2018 for Children and Adolescents With Newly Diagnosed Hodgkin Lymphoma | active not recruiting | Phase 4 | 200 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04881838 | CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL | active not recruiting | Phase 3 | 172 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05029141 | New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 2 | 21 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06357975 | Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) | active not recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02845882 | LBL-2016 for Children or Adolescents in China | active not recruiting | Phase 3 | 150 | Children's Cancer Group, ChinaNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02952508 | Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom(CLOVER-WaM) | active not recruiting | Phase 2 | 120 | Cellectar Biosciences, Inc.INDUSTRY | 11 | Mar 18, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04904588 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide(ACCESS) | active not recruiting | Phase 2 | 300 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04931368 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma(OptiMATe) | active not recruiting | Phase 3 | 331 | Klinikum StuttgartOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480837 | Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma | active not recruiting | — | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT07480850 | Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05257083 | A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma(CARTITUDE-6) | active not recruiting | Phase 3 | 759 | Stichting European Myeloma NetworkNETWORK | 16 | Mar 17, 2026 | clinicaltrials |
| NCT05478512 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL(VIS) | active not recruiting | Phase 2 | 78 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06353022 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma(IFm2022-01) | active not recruiting | Phase 2 | 103 | Nantes University HospitalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05624554 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | active not recruiting | Phase 3 | 300 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Mar 16, 2026 | clinicaltrials |
| NCT02886065 | A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM | active not recruiting | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05364086 | An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study(DiRECT) | active not recruiting | — | 2,100 | University of Rochester NCORP Research BaseOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT05767359 | CAR- PRISM (PRecision Intervention Smoldering Myeloma) | active not recruiting | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT00492050 | Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia | active not recruiting | Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT02446457 | Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03336333 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL(SEQUOIA) | active not recruiting | Phase 3 | 590 | BeiGeneINDUSTRY | 15 | Mar 9, 2026 | clinicaltrials |
| NCT07456982 | The Effect of Relaxation Breathing Exercise on Chemotherapy Induced Nausea and Vomiting | active not recruiting | N/A | 68 | Marmara UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07458542 | Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia | active not recruiting | — | 44 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04460963 | Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches | active not recruiting | N/A | 72 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05306301 | Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients | active not recruiting | Phase 2 | 32 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05502250 | Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission(HOVON164HL) | active not recruiting | Phase 2 | 75 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 3 | Mar 6, 2026 | clinicaltrials |
| NCT05540340 | A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant | active not recruiting | Phase 1 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06067048 | Zanubrutinib in Primary Cold Agglutinin Disease(HOVON169CAD) | active not recruiting | Phase 2 | 25 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 4 | Mar 6, 2026 | clinicaltrials |
| NCT04094961 | Ixazomib + Pomalidomide + Dexamethasone In MM | active not recruiting | Phase 1 / Phase 2 | 52 | Omar Nadeem, MDOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04656951 | Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse(GMMG-DADA) | active not recruiting | Phase 2 | 67 | University of CologneOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04802356 | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients | active not recruiting | Phase 2 | 50 | PETHEMA FoundationOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04914338 | A Multidisciplinary Approach to Improve the Health of Older Adults With Blood Cancers After Stem Cell Transplantation | active not recruiting | N/A | 40 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT05290597 | A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas | active not recruiting | Phase 1 | 40 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06253637 | Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program(DARATALL-VHR) | active not recruiting | Phase 2 | 31 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT02659293 | Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | active not recruiting | Phase 3 | 180 | University of ChicagoOTHER | 2 | Mar 4, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Mar 27, 2026source: clinicaltrials